A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias (NCT06994676)
CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
🩺 Plain-English Summary (8th-Grade Level)
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- City of Hope — Duarte, California
- Stanford Medical Center — Palo Alto, California
- Moffitt Cancer Center — Tampa, Florida
- Northwestern Medicine — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- Washington University in St. Louis — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- Sarah Cannon Cancer Institute — Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (857) 301-6432
Email: rachel.ghiraldi@crossbowtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All High-risk Myelodysplastic Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.